Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1980 1
1981 1
1984 1
1990 1
1994 2
1995 1
1996 2
1997 1
1998 2
2000 1
2001 1
2002 2
2003 2
2004 3
2005 5
2006 3
2007 3
2008 4
2009 6
2010 6
2011 9
2012 8
2013 6
2014 2
2015 9
2016 13
2017 9
2018 12
2019 15
2020 7
2021 6
2022 7
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Lung Squamous Cell Carcinoma"
Page 1
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Kato K, et al. Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30. Lancet Oncol. 2019. PMID: 31582355 Clinical Trial.
BACKGROUND: Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival prospects. We report the final analysis from our study of the immune checkpoint PD-1 inhibitor nivolumab versus chemotherapy in patients wit …
BACKGROUND: Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers poor long-term survival …
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. Waqar SN, et al. Clin Lung Cancer. 2021 May;22(3):170-177. doi: 10.1016/j.cllc.2020.09.013. Epub 2020 Oct 14. Clin Lung Cancer. 2021. PMID: 33221175 Free PMC article. Clinical Trial.
INTRODUCTION: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET-positive squamous cell carcinoma (SCC). PATIENTS AND METHODS: Patients with previously trea …
INTRODUCTION: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c- …
Pembrolizumab-induced agranulocytosis.
Fernández Martínez V, García-Avello Fernández-Cueto A, Valencia Soto CM, Barbadillo Villanueva S, Ochagavía Sufrategui M, Rioja Carrera M, Alonso Buznego LA, Valero Domínguez M. Fernández Martínez V, et al. J Oncol Pharm Pract. 2024 Jun;30(4):767-771. doi: 10.1177/10781552241228774. Epub 2024 Jan 30. J Oncol Pharm Pract. 2024. PMID: 38291678
INTRODUCTION: With the widespread use of anti-programmed death-1 monoclonal antibodies, such as pembrolizumab, rare side effects appear in clinical practice. CASE REPORT: We report the case of a man diagnosed with non-keratinizing squamous lung carcinoma …
INTRODUCTION: With the widespread use of anti-programmed death-1 monoclonal antibodies, such as pembrolizumab, rare side effects appear in …
Camrelizumab: First Global Approval.
Markham A, Keam SJ. Markham A, et al. Drugs. 2019 Aug;79(12):1355-1361. doi: 10.1007/s40265-019-01167-0. Drugs. 2019. PMID: 31313098 Review.
Camrelizumab (AiRuiKa), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being inv …
Camrelizumab (AiRuiKa), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently rece …
PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A. Exposito F, et al. Cancer Res. 2023 Aug 1;83(15):2513-2526. doi: 10.1158/0008-5472.CAN-22-3023. Cancer Res. 2023. PMID: 37311042
Immunotherapy resistance in non-small cell lung cancer (NSCLC) may be mediated by an immunosuppressive microenvironment, which can be shaped by the mutational landscape of the tumor. ...Development of a Pten-null LUSC mouse model revealed that tumors with PTEN loss …
Immunotherapy resistance in non-small cell lung cancer (NSCLC) may be mediated by an immunosuppressive microenvironment, which …
Immunotherapy for Advanced Lung Cancer.
Asmar R, Rizvi NA. Asmar R, et al. Cancer J. 2015 Sep-Oct;21(5):383-91. doi: 10.1097/PPO.0000000000000151. Cancer J. 2015. PMID: 26389763 Review.
Inhibition of these checkpoints can restore and invigorate endogenous antitumor T-cell responses. The immunotherapeutic approach of checkpoint inhibition has become an important treatment option for patients with advanced non-small cell lung cancer, playing a …
Inhibition of these checkpoints can restore and invigorate endogenous antitumor T-cell responses. The immunotherapeutic approach of c …
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S, Kerr KM, Stahel R. Peters S, et al. Cancer Treat Rev. 2018 Jan;62:39-49. doi: 10.1016/j.ctrv.2017.10.002. Epub 2017 Oct 23. Cancer Treat Rev. 2018. PMID: 29156447 Free article. Review.
Non-small cell lung cancer (NSCLC) is one of the most prevalent cancers and is responsible for a large proportion of all cancer-related deaths. ...The use of PD-1 inhibitors such as nivolumab and pembrolizumab in advanced cancers is widespread, and pembrolizumab is …
Non-small cell lung cancer (NSCLC) is one of the most prevalent cancers and is responsible for a large proportion of all cance …
Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer.
Si JF, Xiang J, Wei JW, Hao Y, Song ZB. Si JF, et al. Neoplasma. 2022 Jul;69(4):976-982. doi: 10.4149/neo_2022_220329N348. Epub 2022 May 23. Neoplasma. 2022. PMID: 35603955
We aimed to explore the treatment efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for lung squamous cell carcinoma (SCC) patients and identify potential beneficial subgroups of EGFR-mutated lung …
We aimed to explore the treatment efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for …
EGFR mutations subset in Chinese lung squamous cell carcinoma patients.
Sun Y, Yin X, Wen MM, Zhang J, Wang XJ, Xia JH, Zhang YN, Zhang ZP, Li XF. Sun Y, et al. Mol Med Rep. 2018 Jun;17(6):7575-7584. doi: 10.3892/mmr.2018.8859. Epub 2018 Apr 5. Mol Med Rep. 2018. PMID: 29620244 Free PMC article.
Research has identified that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) possess large benefits for adenocarcinoma (ADC), although little benefit for squamous cell carcinoma (SCC). The aim of the present study was to investigate …
Research has identified that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) possess large benefits for adenocarci …
Research Progress on Mechanism and Management of Adverse Drug Reactions of Anlotinib.
Li S, Wang H. Li S, et al. Drug Des Devel Ther. 2023 Nov 15;17:3429-3437. doi: 10.2147/DDDT.S426898. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 38024530 Free PMC article. Review.
Anlotinib is a novel oral tyrosine kinase inhibitor (TKI) with inhibitory effects on tumor growth tumor angiogenesis. In Phase III clinical trials, anlotinib demonstrated better overall survival and progression-free survival than placebo in patients with advanced non-small …
Anlotinib is a novel oral tyrosine kinase inhibitor (TKI) with inhibitory effects on tumor growth tumor angiogenesis. In Phase III clinic …
141 results